In the assessment of 12-month price targets, analysts unveil insights for 10x Genomics, presenting an average target of ...

Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the life sciences tools & services stocks, including ...

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Thursday, 2026-02-12. Here's what investors need to know before the announcement. Analysts estimate that 10x Genomics ...

8 analysts have shared their evaluations of 10x Genomics (NASDAQ:TXG) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...

・10x Genomics is partnering with Anthropic to integrate its single cell and spatial biology analysis tools into Claude for Life Sciences. ・Researchers can now perform advanced analytical tasks through ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are trying to work out whether 10x Genomics is ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly filed against Vizgen Inc. in 2022, alleging that Vizgen unlawfully used gene ...

Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...

PLEASANTON, Calif., Jan. 12, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a collaboration with Dana-Farber Cancer Institute to ...